Geode Capital Management’s Regencell Bioscience RGC Stock Holding History

Geode Capital Management’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.57M	Buy	422,011 +6,442	+2%	+$155K	﹤0.01%	3137
2026 Q1	$10.6M	Buy	415,569 +2,487	+0.6%	+$70.4K	﹤0.01%	2348
2025 Q4	$8.67M	Sell	413,082 -6,888	-2%	-$112K	﹤0.01%	2479
2025 Q3	$6.49M	Buy	419,970 +28,904	+7%	+$415K	﹤0.01%	2651
2025 Q2	$6.66M	Buy	391,066 +132,058	+51%	+$1.61M	﹤0.01%	2584
2025 Q1	$217K	Buy	+259,008	New	+$71.5K	﹤0.01%	3821
2022 Q4	–	Sell	-259,008	Closed	-$216K	–	4925
2022 Q3	$216K	Hold	259,008	–	–	﹤0.01%	4170
2022 Q2	$238K	Buy	+259,008	New	+$195K	﹤0.01%	4160
2022 Q1	–	Sell	-259,008	Closed	-$224K	–	5013
2021 Q4	$224K	Buy	+259,008	New	+$157K	﹤0.01%	4422

Other funds holding RGC

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

FRM

Fox Run Management Greenwich, Connecticut $603M AUM 32% 1-Year Est. Return

Geode Capital Management's RGC Position: Q2 2026 in Review

Geode Capital Management increased its Regencell Bioscience (RGC) stake by 1.6% in Q2 2026, buying an estimated $155K and bringing the position to 422,011 shares worth $2.57M. The position accounts for ﹤0.01% of the portfolio, ranked #3137.

Geode Capital Management first reported a position in RGC in Q4 2021 and has held it in 9 quarters since. The position peaked at $10.6M in Q1 2026. 35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

Geode Capital Management held 422,011 shares of Regencell Bioscience worth $2.57M as of Q2 2026.
Geode Capital Management bought 6,442 Regencell Bioscience shares in Q2 2026, an estimated $155K.
Regencell Bioscience made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3137 holding.
Geode Capital Management first reported a position in Regencell Bioscience in Q4 2021 and has held it in 9 quarters since.
Geode Capital Management's Regencell Bioscience position peaked at $10.6M in Q1 2026.
35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.